Summary of Envista Holdings Corporation (NVST) Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Results::

Revenue: $751 million, up 10.8% year-over-year (YoY).

Adjusted EBITDA: $111 million, with a margin of 14.8%, a 90 basis point improvement YoY.

Adjusted EPS: $0.38, up over 50% from Q4 2024.

Free Cash Flow: $92 million, down slightly YoY, but strong cash generation with a conversion rate of 114% for the full year.

Full Year 2025 Results::

Total Revenue: $2.7 billion, with core growth of 6.5%.

Adjusted EBITDA: Up 26% YoY, with a margin of 13.7%.

Adjusted EPS: $1.19, up over 60% YoY.

2Strategic Updates and Business Highlights

Value Creation Plan:: Envista is focused on a plan initiated in March 2025, emphasizing growth, operations, and people, with medium-term financial objectives of 2-4% core growth, 4-7% EBITDA growth, and 7-10% EPS growth.

Growth Drivers:: All business segments showed positive growth, with significant contributions from new product introductions and clinical training, which trained 30% more customers in 2025.

R&D Investment:: Continued double-digit increases in R&D investment, with nearly $100 million in revenue from products launched in the last year.

Shareholder Returns:: Initiated a $250 million share repurchase program, returning over $160 million to shareholders in 2025.

3Forward Guidance and Outlook

2026 Guidance::

Core revenue growth expected between 2% to 4%.

Adjusted EBITDA growth projected at 7% to 13%.

Adjusted EPS forecasted between $1.35 to $1.45.

Free cash flow conversion anticipated around 100%.

4Challenges and Points of Concern

Market Volatility:: Potential macroeconomic factors such as tariffs, interest rates, and consumer confidence could impact dental demand.

China Market Risks:: Uncertainty regarding the timing and impact of Value-Based Pricing (VBP) for orthodontics and implants, which could affect revenue and profitability.

Pricing Pressure:: Anticipated moderation in pricing due to the expiration of tariff-related price increases, which could impact future revenue growth.

Adjusted Growth Expectations:: Q4 growth was partly inflated by favorable comparisons from the previous year and specific one-time benefits, suggesting that future growth may not sustain at the same level.

5Notable Q&A Insights

Market Positioning:: Envista outperformed the market in the implant segment, attributed to strategic investments in commercial efforts and customer training.

Profitability of Spark:: Spark's profitability remained stable, with ongoing improvements expected through operational efficiencies and new product launches.

Diagnostic Growth:: The diagnostics segment showed strong growth, but future projections remain cautious, with expectations of low single-digit growth in 2026.

VBP Impact:: The anticipated VBP for ortho and implants is expected to have a net positive effect on revenues, but the timing remains uncertain, complicating forecasts. Overall, Envista Holdings demonstrated strong performance in Q4 2025, with broad-based growth across its segments, while also outlining cautious optimism for 2026 amid potential market challenges and uncertainties.